slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 210,151-210,180
Pages 10,126
Rows per page 30
Component
210,151-210,180 of 303,780
07
Includes a boxed warning disclaimer at the bottom.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
08
The chart shows a steady upward trend in weekly total prescriptions (TRx) over 73 weeks.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & Proof1 hit
09
The slide uses a comparison table structure to quantify the market opportunity for two distinct indications.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & Proof1 hit
10
The slide combines a treatment indication matrix with a donut chart illustrating patient symptom prevalence.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & Proof1 hit
11
The slide includes a mandatory boxed warning disclaimer at the bottom.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & Proof1 hit
13
Includes product branding, dosage options, and a bar chart showing revenue growth.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & Proof1 hit
14
Includes a callout regarding COVID-19 impact on 2020 sales.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & Proof1 hit
15
Alkermes | Investor Presentation Deck | 32 slidesAlkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & Proof1 hit
16
Alkermes | Investor Presentation Deck | 32 slidesAlkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & Proof1 hit
17
Includes a medical illustration of brain pathways related to wakefulness and neurotransmitters.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
18
Includes a molecular visualization of the Orexin 2 receptor.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
19
Data presented as Mean ± SEM; One-way ANOVA used for statistical significance.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
20
The heatmaps visualize EEG frequency power over time, with red indicating high power (arousal) and blue indicating low power.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
21
The slide uses a process flow diagram to show the progression of clinical trials.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Loop · Quick Win Big Bet1 hit
22
The slide outlines a two-stage clinical development process with specific objectives and assessment criteria for each phase.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations Loop · Quick Win Big Bet1 hit
23
Alkermes | Investor Presentation Deck | 32 slidesAlkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
24
The slide outlines the core assets (nemvaleukin alfa, IL-12, IL-18) and the strategic rationale for a spin-off.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
25
The slide uses a human body diagram to map clinical responses (CR, PR, uPR) across various cancer types.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
26
The slide uses a matrix-like layout to categorize studies by 'Potential Registration Enabling Studies' and 'Alternative Dosing Studies'.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
27
Alkermes | Investor Presentation Deck | 32 slidesAlkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
28
The slide outlines the strategic rationale for a spin-off, emphasizing focus and profitability.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
29
The chart illustrates the shift from a single-product revenue base to a more diversified portfolio including VIVITROL, ARISTADA, VUMERITY, and LYBALVI.Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
30
Includes disclaimer regarding non-GAAP reconciliation and specific business context (oncology spin-off, INVEGA royalties).Alkermes | Investor Presentation Deck | 32 slides · Alkermes
Research note Investor relations 1 hit
01
Allbirds | Investor Presentation Deck | 14 slidesAllbirds | Investor Presentation Deck | 14 slides · Allbirds
Pitch deck Investor relations 1 hit
02
Allbirds | Investor Presentation Deck | 14 slidesAllbirds | Investor Presentation Deck | 14 slides · Allbirds
Pitch deck Investor relations 1 hit
03
Allbirds | Investor Presentation Deck | 14 slidesAllbirds | Investor Presentation Deck | 14 slides · Allbirds
Pitch deck Investor relations 1 hit
04
Includes a financial table comparing Q4 2022 and Full Year 2022 results.Allbirds | Investor Presentation Deck | 14 slides · Allbirds
Pitch deck Investor relations Beat · ProblemLoop · Why Now1 hit
05
Allbirds | Investor Presentation Deck | 14 slidesAllbirds | Investor Presentation Deck | 14 slides · Allbirds
Pitch deck Investor relations Beat · SolutionLoop · Why Now1 hit
06
Uses a 'Where we are today' vs 'Where we are going' structure to frame the company's evolution.Allbirds | Investor Presentation Deck | 14 slides · Allbirds
Pitch deck Investor relations Beat · RoadmapLoop · Why Now1 hit
07
The slide uses a bulleted list to define the target audience persona.Allbirds | Investor Presentation Deck | 14 slides · Allbirds
Pitch deck Investor relations Beat · Market Size1 hit